Topic
Tuberculosis screening tests
💡 What You Need to Know
- Purpose of Screening: Tuberculosis (TB) screening tests are crucial for identifying individuals with latent TB infection (LTBI) or active TB disease, even before symptoms appear.
- Target Populations: Screening is particularly recommended for close contacts of active TB cases, healthcare workers, immunocompromised individuals, and those born in or who have traveled to high TB prevalence countries.
- Primary Tests Available: The two main types of TB screening tests are the Tuberculin Skin Test (TST), also known as the Mantoux test, and Interferon-Gamma Release Assays (IGRAs), such as QuantiFERON-TB Gold Plus or T-SPOT.TB.
- Importance of Early Detection: Early detection allows for timely treatment of LTBI to prevent progression to active disease, and prompt treatment of active TB to prevent further transmission.
🤒 Associated Symptoms
- Persistent Cough: A cough lasting more than three weeks, which may or may not produce sputum.
- Unexplained Fever and Chills: Often low-grade fever, particularly in the afternoon or evening, accompanied by chills.
- Night Sweats: Profuse sweating during sleep, often soaking clothes and bedding.
- Unintentional Weight Loss: Significant loss of body weight without changes in diet or exercise.
- Fatigue and Malaise: Persistent tiredness, weakness, and a general feeling of being unwell.
- Loss of Appetite: A noticeable decrease in desire to eat.
- Hemoptysis: Coughing up blood or blood-streaked sputum, indicating more advanced disease.
🛡 Crucial Precautions
- Prior BCG Vaccination: Individuals who have received the Bacillus Calmette-Guérin (BCG) vaccine may have a false-positive TST result; IGRAs are generally preferred in these cases.
- Immunosuppression: Patients with weakened immune systems (e.g., HIV, organ transplant recipients, those on immunosuppressive medications) may have a false-negative TST due to anergy; IGRAs may be more reliable.
- Recent Live-Virus Vaccination: TST should be delayed for 4-6 weeks after administration of live-virus vaccines (e.g., measles, mumps, rubella, varicella) to avoid a false-negative reaction.
- Proper TST Administration and Reading: The TST must be administered by trained personnel using the correct intradermal technique and read accurately within 48-72 hours by a healthcare professional.
- Two-Step TST: For individuals who will be periodically retested (e.g., healthcare workers), a two-step TST may be recommended to establish a baseline and avoid a 'booster phenomenon'.
🍽 Dietary Directions & Restrictions
- No Fasting Required: Neither the Tuberculin Skin Test (TST) nor Interferon-Gamma Release Assays (IGRAs) require any specific dietary restrictions or fasting prior to their administration.
- Normal Hydration: Patients should maintain their usual fluid intake unless otherwise advised for other concurrent medical conditions or procedures.
- Medication Adherence: Continue all prescribed medications as usual, unless specifically instructed by a healthcare provider.
- General Well-being: While not a restriction, maintaining a balanced diet and good hydration supports overall health, which can be beneficial for immune response, though not directly impacting test accuracy.
⚠️ Attendant Guidelines
- TST Reading Appointment: It is critical to return to the clinic within 48 to 72 hours after the TST injection for the test site to be accurately read by a healthcare professional. Failure to do so will require retesting.
- Avoid Manipulation of TST Site: Do not scratch, rub, or apply creams, ointments, or bandages to the TST injection site, as this can interfere with the test result.
- IGRA Blood Draw Procedure: For IGRA tests, a standard blood draw will be performed, similar to other routine blood tests. Minimal discomfort is expected.
- Positive Result Follow-up: A positive screening test (TST or IGRA) does not confirm active TB disease. Further diagnostic tests, such as a chest X-ray and sputum analysis, will be required to differentiate between latent TB infection and active disease.
- Inform Healthcare Provider: Always inform your healthcare provider about any prior BCG vaccination, history of TB exposure, or immunosuppressive conditions, as these factors influence test interpretation.
🩺 Physician's Perspective
- Comprehensive Risk Assessment: Always integrate individual patient risk factors, including exposure history, comorbidities, travel history, and immune status, when selecting and interpreting TB screening tests.
- Test Selection Rationale: Choose between TST and IGRA based on patient-specific factors (e.g., BCG vaccination history, likelihood of follow-up, immunosuppression) and adherence to local public health guidelines.
- Confirmation of Active Disease: Emphasize that a positive screening test necessitates further diagnostic evaluation (e.g., chest radiography, sputum microscopy, culture, NAAT) to definitively diagnose active TB disease.
- Latent TB Infection Management: Discuss the benefits and risks of treatment for latent TB infection (LTBI) with high-risk individuals to prevent progression to active disease, considering drug interactions and patient adherence.
- Public Health Reporting: Active TB is a reportable disease; ensure prompt notification to public health authorities for contact investigation and disease surveillance.
🎓 Academic & Nursing Corner
- Patient Education Mastery: Develop comprehensive patient education skills to explain the purpose, procedure, potential results, and critical follow-up requirements for both TST and IGRA tests.
- TST Administration Proficiency: Practice and master the precise intradermal injection technique for TST, ensuring the correct dose and formation of a distinct wheal.
- Accurate TST Reading and Documentation: Learn to accurately measure the induration (not erythema) in millimeters at the appropriate 48-72 hour window and meticulously document the findings.
- IGRA Specimen Handling: Understand and adhere to proper blood collection, handling, and transport protocols for IGRA samples to ensure test integrity and accurate results.
- Adverse Reaction Monitoring: Be prepared to identify and manage any rare adverse reactions to the TST (e.g., severe local reactions) or blood draw (e.g., vasovagal syncope).
🔬 Clinical Reference Index
- TST Induration Interpretation Criteria:
- ≥5 mm induration: Positive for close contacts of active TB cases, immunocompromised individuals (e.g., HIV-positive), recent TB converters, and persons with fibrotic changes on chest X-ray consistent with prior TB.
- ≥10 mm induration: Positive for recent immigrants from high-prevalence countries, intravenous drug users, residents/employees of high-risk congregate settings (e.g., prisons, nursing homes), children <4 years of age, and persons with clinical conditions that increase TB risk (e.g., diabetes, silicosis).
- ≥15 mm induration: Positive for persons with no known risk factors for TB.
- Interferon-Gamma Release Assays (IGRAs): Blood tests that measure the immune response to specific TB antigens (ESAT-6, CFP-10). Results are reported as positive, negative, or indeterminate.
- Mycobacterium tuberculosis: The slow-growing, acid-fast bacillus that is the primary causative agent of tuberculosis.
- Latent Tuberculosis Infection (LTBI): A state where TB bacteria are present in the body but are inactive and cause no symptoms. Individuals with LTBI are not infectious but can progress to active TB disease.
- CDC Guidelines: Refer to the latest Centers for Disease Control and Prevention (CDC) guidelines for comprehensive recommendations on TB screening, diagnosis, and treatment.